Recently, the subcutaneous administration of a recombinant Ang1 variant protein (‘Ang-F1-Fc-F1’, also called ‘BowAng1’) on its own had no effect on primary tumors, but as a concurrent treatment diminished the anti-angiogenic and anti-tumor efficacy of an anti-Ang2 antibody (Daly et al, 2013). This evidence concerns the gene ANGPT2 and neoplasm.